Alaunos Therapeutics, Inc.
TCRT Healthcare Biotechnology
Alaunos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5,000.00, down 50.0% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS grew 34.9% and free cash flow grew 57.2%, each against the same quarter a year earlier.
Follow TCRT
Alaunos Therapeutics, Inc. (TCRT) EV/Sales
As of 16 October 2026, Alaunos Therapeutics, Inc. (TCRT) trades at a EV/Sales of 1,552×. Over the past ten years it has ranged from 3.9× (December 2023) to 2,388× (July 2024); the current reading is higher than 89% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1,455× | (8.17%) |
| FY2024 | 1,584× | 14,859.93% |
| FY2023 | 10.6× | (65.05%) |
| FY2022 | 30.3× | (37.70%) |
| FY2021 | 48.6× | 16.17% |
| FY2018 | 41.9× | (50.22%) |
| FY2017 | 84.1× | (8.77%) |
| FY2016 | 92.2× | (55.72%) |
| FY2015 | 208× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 1,455× | (0.21%) |
| Mar 2025 | 1,458× | (7.98%) |
| Dec 2024 | 1,584× | (32.29%) |
| Jun 2024 | 2,340× | 1.12% |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| EVGN Evogene Ltd. compare | −2.8× |
| SYBX Synlogic, Inc. compare | −0.2× |
| ENVB Enveric Biosciences, Inc. compare | −0.1× |
| FBLG FibroBiologics Inc. compare | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| TRAW Traws Pharma, Inc. compare | 0.3× |
| LEXX Lexaria Bioscience Corp. compare | 2.4× |
| TCRT Alaunos Therapeutics, Inc. | 1,552× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)